Sugi Predict

Sugi Predict / Compounds / SCHEMBL2664595

SCHEMBL2664595

SCHEMBL2664595

O=C(Nc1cnccn1)c1cc(OCc2ccccc2Cl)cc(OCc2ccccc2Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 3/20 0.58
▸ KMT2A Q03164 1/20 0.53
▸ RARA P10276 1/20 0.52
▸ RARB P10826 1/20 0.52
▸ RARG P13631 1/20 0.52
▸ NR4A2 P43354 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SGMS2 Q8NHU3 1/20 0.48
▸ SIRT2 Q8IXJ6 1/20 0.48
▸ TSHR P16473 3/20 0.48
▸ CHRNB2 P17787 1/20 0.48
▸ CHRNB4 P30926 1/20 0.48
▸ CHRNA3 P32297 1/20 0.48
▸ CHRNA4 P43681 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664596 0.86 GCK (0.57) GCKKMT2ARARARARBRARG
SCHEMBL2664598 0.85 GCK (0.61) GCKKMT2ARARARARBRARG
SCHEMBL2664606 0.85 SGMS2 (0.52) GCKKMT2ARARARARBRARG
SCHEMBL12615802 0.84 GCK (0.67) GCKKMT2ARARARARBRARG
SCHEMBL2664601 0.83 GCK (0.64) GCKKMT2ARARARARBRARG
SCHEMBL2664637 0.82 GCK (0.55) GCKKMT2ARARARARBRARG
SCHEMBL2664865 0.81 GCK (0.65) GCKKMT2ARARARARBRARG
SCHEMBL2664599 0.81 GCK (0.56) GCKKMT2ARARARARBRARG
SCHEMBL1792201 0.81 GCK (0.64) GCKKMT2ARARARARBRARG
SCHEMBL2664619 0.80 GCK (0.73) GCKRARARARBRARGSGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 — — US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 — — US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 — — US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 — — US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 — — US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 — — US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 — — US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 — — US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 — — US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 GCK 2/4885KMT2A 1974/4885RARA 3925/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 GCK 2/4885KMT2A 1974/4885RARA 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.